Dr Lal Pathlabs Ltd's Q4FY25 Quarter Results
- 26 Apr 2025
Result Summary
- Dr Lal Pathlabs Ltd reported a 9.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.6%.
- Its expenses for the quarter were down by 8.2% QoQ and up 5.2% YoY.
- The net profit decreased 12.5% QoQ and increased 50.8% YoY.
- The earnings per share (EPS) of Dr Lal Pathlabs Ltd stood at 10.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 563.80 | 621.80 | 505.20 | -9.3% | 11.6% |
Total Expenses | 443.90 | 483.50 | 422.00 | -8.2% | 5.2% |
Profit Before Tax | 119.90 | 138.30 | 83.20 | -13.3% | 44.1% |
Tax | 34.10 | 40.20 | 26.30 | -15.2% | 29.7% |
Profit After Tax | 85.80 | 98.10 | 56.90 | -12.5% | 50.8% |
Earnings Per Share | 10.10 | 11.60 | 6.80 | -12.9% | 48.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr Lal Pathlabs Ltd is a prominent name in the Indian healthcare sector, specifically known for its diagnostic and testing services. The company operates a vast network of laboratories and collection centers across the country, providing a wide range of pathology tests and healthcare diagnostics. Dr Lal Pathlabs has established itself as a leader in the diagnostics industry, catering to the growing demand for healthcare services in India. As of the latest known developments, the company has been focusing on expanding its service capabilities and geographical reach to enhance access to quality diagnostic services. However, specific recent developments beyond this general information are not available.
Revenue
In Q4FY25, Dr Lal Pathlabs Ltd reported a total income of ₹563.80 crores, which represents a decrease of 9.3% from the previous quarter (Q3FY25) where the total income was ₹621.80 crores. On a year-over-year basis, the total income saw an increase of 11.6% compared to Q4FY24, when it was ₹505.20 crores. This indicates growth in revenue year-over-year despite a quarter-over-quarter decline. Such fluctuations in revenue can be observed as part of the company's financial performance cycle.
Profitability
During Q4FY25, the company achieved a profit before tax of ₹119.90 crores, down by 13.3% quarter-over-quarter from Q3FY25's profit before tax of ₹138.30 crores. Year-over-year, there was a significant increase of 44.1% compared to Q4FY24, when the profit before tax was ₹83.20 crores. The tax paid in Q4FY25 amounted to ₹34.10 crores, which is a reduction of 15.2% from the preceding quarter. Profit after tax for Q4FY25 was ₹85.80 crores, reflecting a 12.5% decrease from Q3FY25 but a notable 50.8% increase from Q4FY24. The earnings per share in Q4FY25 were ₹10.10, compared to ₹11.60 in Q3FY25 and ₹6.80 in Q4FY24, demonstrating a year-over-year increase of 48.5%.
Operating Metrics
Total expenses for Dr Lal Pathlabs Ltd in Q4FY25 were ₹443.90 crores, marking an 8.2% decrease from Q3FY25's total expenses of ₹483.50 crores. On a year-over-year comparison, total expenses increased by 5.2% from Q4FY24's ₹422.00 crores. The reduction in expenses from the previous quarter could be attributed to various operational factors. Key financial metrics such as the P/E ratio, debt-to-equity ratio, and current ratio are not provided in the data, and thus, cannot be calculated or analyzed. The trends in operating metrics show a disciplined approach in managing expenses, which is crucial for maintaining profitability and operational efficiency.
